Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

But on Wednesday, May 28 Moderna revealed the HHS has terminated the award for late-stage development and right to purchase ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Instead, Stealth submitted a new drug application seeking approval of elamipretide, and the FDA issued its refusal-to-file ...

In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Siemens Healthineers has deployed its first mobile stroke unit in the U.S., with an ambulance equipped with its own CT ...